Cytomegalovirus (CMV) remains a major concern in both solid organ transplantation (SOT) and hematopoietic stem cell transplant (HSCT), primarily due to challenges related to treatment selection and monitoring, management of drug-related adverse events, and resistant/refractory disease. To minimize the impact of CMV infection in patients with HSCTs or kidney transplants, the interdisciplinary care team managing these patients must have guidance on incorporating novel antiviral therapies into prevention and treatment schemas for CMV.
In this CME Outfitters recorded Grand Rounds series, expert faculty will emphasize the burden of CMV in kidney transplantation and HSCT, review the benefits and limitations of current antiviral agents, and discuss the role of novel antivirals (e.g., letermovir and maribavir) for managing CMV. Additionally, case studies will demonstrate how to integrate novel antivirals into clinical practice to improve quality of care and outcomes.
At the conclusion of this activity, learners will be able to better:
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Infectious disease clinicians including physicians, physician associates (PAs), nurse practitioners (NPs), nephrologists, renal specialists, nurses, and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-042-H01-P).
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 08/13/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Papanicolaou reports the following financial relationships:
Consultant: Armata Pharmaceuticals, Inc.; Genentech, Inc.; MSD; SymBio Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and Trellis Bioscience, Inc.
Research Support: MSD (paid to institution)
Dr. Kotton reports the following financial relationships:
Advisory Board: Abbott and Roche Diagnostics
Consultant: Abbott; Abcuro; AiCuris; AMIVAS; BeiGene; Biotest; Evrys Bio; ExeVir Bio; Generate:Biomedicines; Hookipa Pharma Inc.; IntegerBio; Kamada Pharmaceuticals; Merck & Co., Inc.; QIAGEN; Synklino; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: AiCuris; BeiGene; Biohope Scientific; Kamada Pharmaceuticals; and Roche Diagnostics
Speakers Bureau: Kamada Pharmaceuticals
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Susan Perry (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
GRV-040-081324-44
